Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March). This quarter, 6 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: three from China, two from the EU, and one from Australia:
Vilobelimab (Gohibic)
Garadacimab (Andembry)
Finotonlimab (新替妥)
Siltartoxatug (Sintetol)
Sipavibart (Kavigale)
Teprotumumab N01 (Sycume)
Q1 2025 saw several large collaborations and acquisitions of up to USD$3.1 billion in value. The majority of collaborative efforts focused on developing novel platforms such as bispecific antibody and ADC engineering.
Gain exclusive insights into current trends such as:
6 novel antibody drugs approved for the first time in Q1
Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$3.1B
Novel platforms such as bispecific antibody and ADC engineering
Recent research into obesity and COVID-19 treatments
A list of antibody drugs in regulatory review to keep an eye out for in Q2 2025
Biointron’s Q2 2026 Antibody Industry Trends report aims to explore the events a……
Autoimmune diseases are a group of disorders in which the immune system targets ……
Antibodies are important raw materials for many in vitro diagnostic (IVD) applic……
For decades, many disease-driving proteins were described as undruggable because……
You can also contact us on the Scientist and Science Exchange marketplaces.